Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 9612002

Bioactive bone cements.

E J Harper
View original source ↗Export metadata ↓

Abstract

Poly(methylmethacrylate) (PMMA) bone cement, used to fix implants into the bone, produces good surgical results if used correctly. However, prostheses do eventually become loose and the breakdown of the cement mantle is a factor in this failure. Limitations of PMMA cement, which lead to problems with the fixation of the implant, include its mechanical characteristics and its influence upon surrounding bone, associated with the polymerization reaction. A bioactive bone cement is particularly designed to produce a better interface between the cement and bone. However, an improvement in mechanical properties, especially fatigue, creep and fracture toughness, are an added necessary requirement to increase the lifetime of a cemented implant. The development of a bioactive cement has been conducted mainly in two ways; firstly, to improve existing PMMA cement by the addition of various bioactive agents and secondly, to design an alternative matrix for the bioactive material to be combined with. The most promising investigations which have been conducted, along with their relative benefits and drawbacks, are discussed.

Explore related subjects

Biocompatible MaterialsBiomechanical PhenomenaBisphenol A-Glycidyl MethacrylateBone CementsBone and BonesGrowth HormoneHydroxyapatitesJoint ProsthesisMaterials TestingPolymethyl MethacrylateJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

E J Harper. 1998. Bioactive bone cements.. https://doi.org/10.1243/0954411981533881

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1999

Study of fatigue resistance of chemical and radiation crosslinked medical grade ultrahigh molecular weight polyethylene.

The aim of this work is to understand the role of chemical and radiation induced crosslinking on the fatigue crack propagation resistance of medical grade ultrahigh molecular weight polyethylene (UHMWPE). In recent years, the need to improve the tribological performance of UHMWPE used in total joint replacements has resulted in the widespread utilization of crosslinking as a method to improve wear resistance. Although crosslinking has been shown to drastically improve the wear resistance of the polymer, the potential trade-off in fatigue properties has yet to be addressed. Fatigue crack propagation resistance is a concern in tibial inserts where large cyclic stresses are sufficient to drive the growth of subsurface cracks that potentially contribute to delamination wear mechanisms. For clinical relevance, the combined effects of sterilization and aging are examined in two commercially available crosslinked resins. Nonsterile and unaged resins serve as a control. To evaluate the effect of crosslinking, a comparison is made to uncrosslinked resins. Scanning electron microscopy is used to provide an understanding of fatigue fracture mechanisms in the crosslinked polymers. The results of this study show that the current level of crosslinking used in orthopedic resins for enhanced wear resistance is not beneficial for fatigue crack propagation resistance.

Biocompatible Materials↗
PubMed1999

Preparation of nanoparticles consisted of poly(L-lactide)-poly(ethylene glycol)-poly(L-lactide) and their evaluation in vitro.

This study describes the preparation and the evaluation of biodegradable poly(L-lactide)-poly(ethylene glycol)-poly(L-lactide) copolymer (PLA-PEG-PLA) nanoparticles containing progesterone as a model drug. PLA and PLA-PEG-PLA copolymers, whose PEG content ranged from 5.2 to 25.8% (w/w), were polymerized in our laboratory. PEG with weight-average molecular weight (Mw) 6600 or 20 000 was introduced as a hydrophilic segment into a hydrophobic PLA homopolymer. A solvent evaporation method was used to prepare the nanoparticles. The drug trapping efficiencies were around 70% and the weight-averaged mean diameters of the nanoparticles were less than 335 nm. The amount of drug released increased as the PEG content and Mw of PLA-PEG-PLA copolymers increased and the total Mw of copolymers of nanoparticles decreased. The initial burst of drug release was reduced by removing the low Mw fraction from the polymer. During the release test, both the extent to which the copolymers were degraded and the size of the nanoparticles were increased slightly by increasing the content of PEG in the polymers. Drug release from the nanoparticles could potentially be controlled by changing the PEG content, PEG Mw and total Mw of the copolymer. The molecular weight distribution (Mw/Mn, Mn: number-average molecular weight) of copolymers was also an important factor for controlled release.

Biocompatible Materials↗
PubMed1999

Biodegradable monodispersed nanoparticles prepared by pressure homogenization-emulsification.

The aim of the present work was to investigate the preparation of nanoparticles (NP) as potential drug carriers for proteins. The hydrophilic protein bovine serum albumin (BSA) was chosen as the model drug to be incorporated within NP. Owing to the high solubility of the protein in water, the double emulsion technique has been chosen as one of the most appropriate method. In order to reach submicron size we used a microfluidizer as a homogenization device with a view to obtaining NP with a very high grade of monodispersity. Two different biodegradable polymers, poly[D, L-lactic-co-glycolic acid] 50/50 (PLGA) and poly[epsilon-caprolactone] (PCL) has been used for the preparation of the NP. The drug loading has been optimized by varying the concentration of the protein in the inner aqueous phase, the polymer in the organic phase, the surfactant in the external aqueous phase, as well as the volume of the external aqueous phase. The BSA encapsulation efficiency was high (>80%) and release profiles were characterized by a substantial initial burst release for both PLGA and PCL NP. A higher release was obtained at the end of the dissolution study for PLGA NP (92%) compared with PCL NP (72%).

Biocompatible Materials↗